GHR and steatosis: In a model of systemic GHR mutations that impair or inhibit activation of STAT5, Barclay and colleagues demonstrate the development of a NASH phenotype, with steatosis, inflammation, and hepatocellular ballooning, in conjunction with upregulation of genes relating to lipid uptake, transport, and synthesis [52].